IOV-4001 vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
IOV-4001
Developed by Iovance Biotherapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT05361174 (registry estimate)
No aligned efficacy figure on record for this race.
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | IOV-4001 | Penpulimab |
|---|---|---|
| PFS, median | —Not reported | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 |
| OS, median | —Not reported | —Not posted · NCT03866993 |
| ORR | —Not reported | —Not posted · NCT03866993 |
| Duration of response, median | —Not reported | —Not posted · NCT03866993 |
PFS, median
- IOV-4001
- —Not reported
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
OS, median
- IOV-4001
- —Not reported
- Penpulimab
- —Not posted · NCT03866993
ORR
- IOV-4001
- —Not reported
- Penpulimab
- —Not posted · NCT03866993
Duration of response, median
- IOV-4001
- —Not reported
- Penpulimab
- —Not posted · NCT03866993
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
IOV-4001: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Penpulimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IOV-4001's landscape · Penpulimab's landscape